Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > NY Times article on VRX
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by CookieMonsteron Aug 01, 2016 10:03am
95 Views
Post# 25100147

NY Times article on VRX

NY Times article on VRXhttps://www.nytimes.com/2016/07/31/business/how-valeant-cashed-in-twice-on-higher-drug-prices.html?_r=0
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities